louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04837183: Catheter Ablation of Ventricular Arrhythmia Reduces Skin Sympathetic Activity
Official title: Catheter Ablation of Ventricular Arrhythmia Reduces Skin Sympathetic Activity
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Ventricular Tachycardia
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Cedars-Sinai Medical Center
First posted: 2021-04-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients will undergo catheter ablation to control VA recommended by current guideline.

Brief summary: This study is being done to determine whether there is an increase in sympathetic nerve activity before the onset of ventricular arrhythmias or irregular heartbeat rhythm. In addition, this study is looking at the relationship between sympathetic nerve activity and how patients with ventricular arrhythmias respond to catheter ablation treatment.


Eligibility criteria: Inclusion Criteria:

* Patients who have non-sustained or sustained VA (VA ≥ 30s or receiving appropriate ICD therapies) are presented to the clinic or admitted to the hospital within 7 days of episodes.
* The causes of VA are associated with structural heart diseases including ischemic or nonischemic cardiomyopathy (idiopathic cardiomyopathy, hypertrophic cardiomyopathy, cardiac sarcoidosis or amyloidosis, and arrhythmogentic right ventricular dysplasia).
* Subjects are 18 years of age and older.

Exclusion Criteria:

* Female patients who is pregnant or of childbearing potential and not on a reliable form of birth control.
* Allergic to skin patch electrodes.
* Vulnerable populations (fetuses, neonates, pregnant women, prisoners, institutionalized individuals).

Primary outcomes:
measure: Change in amplitude of skin sympathetic nerve activity
timeFrame: Baseline, 24 hours post catheter ablation and approximately 3-6 months post-operative
measure: Change in LF/HF ratio
timeFrame: Baseline, 24 hours post catheter ablation and approximately 3-6 months post-operative
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Yong-Mei Cha, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05541783: Laparoscopic-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric Cancer
Official title: A Multi-center Prospective Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopic-assisted Distal Gastrectomy (LADG) and Totally Laparoscopic Distal Gastrectomy (TLDG) for Gastric Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastric Cancer
Keywords: Gastric cancer，Laparoscopic distal gastrectomy
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2022-09-15
Enrollment: 213
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is comparing the short-term quality of life between laparoscopy-assisted distal gastrectomy and totally laparoscopic distal gastrectomy for gastric cancer.


Eligibility criteria: Inclusion Criteria:

1. Aged 20-80 years;
2. Patients had an Eastern Cooperative Oncology Group performance status score of 0 or 1;
3. Patients had histologically confirmed gastric adenocarcinoma (tumor size\<5cm) at clinical stage I-III with T1-4aN0-2M0 excluding T4b or N3 tumors, according to the of the American Joint Committee on Cancer classification system, eighth edition;
4. Patients were expected to undergo laparoscopic distal gastrectomy with D2 lymphadenectomy.

Exclusion Criteria:

1. Patients had bulky regional lymph nodes (larger than 3 cm at the long diameter) or possible distant metastasis in preoperative evaluation
2. Patients had history of chemotherapy, radiotherapy, immunotherapy or target therapy;
3. Patients had any concurrent or previous malignant tumor;
4. Patients had unstable cardiovascular, respiratory, kidney, or liver disease and poorly controlled hypertension, diabetes, mental disorders; history of upper abdominal surgery (except laparoscopic cholecystectomy).
5. Patients were histologically proven gastric adenocarcinoma (by preoperative gastrofiberscopy).

Primary outcomes:
measure: Scores on the physical function and pain symptom scales of EORTC QLQ-C30 questionnaire
timeFrame: 30 days postoperatively
Secondary outcomes:
measure: Scores on the other scales of EORTC QLQ-C30 questionnaire postoperatively
timeFrame: 30 days postoperatively
measure: Scores on EORTC QLQ-C30 questionnaire
timeFrame: 7 days and 90 days postoperatively
measure: Scores on the scales of EORTC QLQ-STO22 questionnaire postoperatively
timeFrame: 7，30 and 90 days postoperatively
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
affiliation: Fudan University
name: Dazhi Xu, PHD, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01853683: Is Interval Appendectomy Necessary?
Official title: Interval Appendectomy in Children, is it Really Necessary? A Randomized, Noninferiority Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Appendicitis
Keywords: General Surgery
Lead sponsor: Children's Hospital of Eastern Ontario
Sponsor class: OTHER
First posted: 2013-05-15
Enrollment: 5
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Appendicitis is one of the most common surgical problems in children, with 20-35% of patients having perforated by the time they present to a doctor. In these cases, the patient is often treated non-surgically with antibiotics. Once a patient has improved, it is not known whether it is better to perform an interval appendectomy (IA) or to continue a watchful waiting approach. The purpose of this trial is to determine if expectant nonoperative management (watchful waiting) is not inferior compared to IA management after successful conservative treatment of appendiceal mass at admission.


Eligibility criteria: Inclusion Criteria:

* Under 18 years of age
* Perforated appendicitis where the treating physician chooses to follow the conservative approach rather than performing an immediate appendectomy

Exclusion Criteria:

* Uncertainty about the diagnosis
* The need for laparotomy/laparoscopy for another reason
* Perforated appendicitis with diffuse abdominal fluid on imaging associated with a clinical picture of severe sepsis
* Another medical condition that may affect the decision to operate e.g., inflammatory bowel disease
* A comorbidity or chronic illness that contraindicates the watchful waiting approach, e.g, diabetes or cardiac problems

Primary outcomes:
measure: Recurrent appendicitis for the conservative group
timeFrame: During a year of follow-up
measure: Operative complications for the operative group
timeFrame: During a year of follow-up
Secondary outcomes:
measure: Duration of hospital stay
timeFrame: This is the patients' original hospital stay, and re-admission for interval appendectomy when applicable, an expected average of 5 days
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: Children's Hospital of Eastern Ontario
state: Ontario
Study officials:
affiliation: Children's Hospital of Eastern Ontario
name: Ahmed Nasr, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06930183: Awake Thoracic Epidural Anesthesia Versus General Anesthesia in Thoracotomy
Official title: Awake Thoracic Epidural Anesthesia Versus General Anesthesia in Thoracotomy: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Awake
Thoracic Epidural Anesthesia
General Anesthesia
Thoracotomy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-16
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare awake thoracic epidural anesthesia and general anesthesia in thoracotomy.

Detailed description: The severity of acute postoperative pain is a causative factor for chronic postsurgical pain, and it has been observed that the incidence of chronic postsurgical pain is very high after thoracotomy. Effective management of acute post-operative pain is a must in these patients.

Thoracic epidural analgesia (TEA) is used as an adjunct to general anesthesia (GA) in thoracic surgery. However, tthe horacic epidural blockade has been rarely utilized as a sole method to provide anesthesia for major thoracic procedures

Eligibility criteria: Inclusion Criteria:

* Age from 18 to 75 years old.
* Both genders.
* American Society of Anesthesiologists (ASA) physical status classification II or III.
* Scheduled for thoracotomy.

Exclusion Criteria:

* Difficult airway management,
* Hemodynamically unstable patients, obesity (body mass index \>30).
* Absolute contraindication to thoracic epidural anesthesia such as (patient refusal, allergy to local anesthetics, coagulopathy, active neurologic disorders, skin infection at insertion site, uncooperative patients, uncontrolled cough, and unfavorable anatomy for thoracic epidural).
* Neurological disorders: risk of seizure, unable to cooperate, intracranial mass or brain edema, extensive pleural adhesions or previous pulmonary resections, hypoxemia (PaO2 \<60) or hypercarbia (PaCO2 \>50)
* Poor cardiac function (ejection fraction less than 50%).
* Patients with bad pulmonary function tests.

Primary outcomes:
measure: Assessment the change in pulmonary function
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: Heart rate
timeFrame: Till the end of surgery (Up to 2 hours)
measure: Mean arterial pressure
timeFrame: Till the end of surgery (Up to 2 hours)
measure: Degree of pain
timeFrame: 48 hours postoperatively
measure: Total morphine consumption
timeFrame: 48 hours postoperatively
measure: Time to 1st rescue analgesia
timeFrame: 48 hours postoperatively
measure: Incidence of adverse events
timeFrame: 48 hours postoperatively
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo University
Study officials:
References:
Clinical trial NCT02323997: Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study
Official title: Human Papillomavirus-Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Cancer
Keywords: HPV
cervical cancer
human papillomavirus
cervical pre-cancer
cervical neoplasia
Lead sponsor: University of Bern
Sponsor class: OTHER
Collaborators: name: Federal Office of Public Health, Switzerland
First posted: 2014-12-24
Enrollment: 767
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with histologically confirmed CIN3+ lesions

Brief summary: This study will investigate the types of HPV in samples from women with cervical pre-cancer and cancer and gather information to help investigate the impact of HPV vaccination in Switzerland.


Eligibility criteria: Inclusion Criteria:

* Participant is willing and able to give informed consent for participation in the study.
* Participant is literate in German, French, Italian or English.
* Female, aged 18 years or above.
* Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive carcinoma of the cervix.
* Participant resides in the canton Zurich, Geneva, Basel, Baselland, Luzern or Ticino.

Exclusion Criteria:

* None

Primary outcomes:
measure: Human papillomavirus presence and type
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Allschwil
country: Switzerland
facility: Viollier AG
state: Baselland
city: Basel
country: Switzerland
facility: Universitätsspital Basel
city: Geneva
country: Switzerland
facility: Viollier Weintraub SA
city: Geneva
country: Switzerland
facility: HUG - Hôpitaux Universitaires de Genève
city: Liestal
country: Switzerland
facility: Kantonsspital Baselland
city: Locarno
country: Switzerland
facility: Istituto cantonale di patologia
city: Luzern
country: Switzerland
facility: Kantonsspital Luzern
city: Zurich
country: Switzerland
facility: Institute of Pathology Enge
city: Zurich
country: Switzerland
facility: Institut für klinische Pathologie Medica
city: Zürich
country: Switzerland
facility: Universitätsspital Zürich
Study officials:
affiliation: University of Bern, Institute of Social and Preventive Medicine
name: Nicola Low
role: PRINCIPAL_INVESTIGATOR
References:
citation: Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N; CIN3+plus study group. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer. 2019 Jan 30;19(1):111. doi: 10.1186/s12885-018-5248-y.
Clinical trial NCT03691597: Patient Satisfaction ,Marginal Integrity ,Shade Matching and Gingival Health of Zirconia Reinforced Lithium Silicate Bridges Cemented Using Bioactive Cement and Adhesive Resin Cement
Official title: Patient Satisfaction ,Marginal Integrity ,Shade Matching and Gingival Health of Zirconia Reinforced Lithium Silicate Bridges Cemented Using Bioactive Cement and Adhesive Resin Cement
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Patient Satisfaction ,Marginal Integrity, Shade Match and Gingival Health
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-10-02
Enrollment: 36
Sex: ALL
Minimum age (years): 19
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bioactive cement have been introduced recently into the market according to the manufacture it is assumed that it stimulates mineral apatite formation and the natural remineralization process at the material-tooth interface that knits together the restoration and the tooth, penetrates and fills micro-gaps, reduces sensitivity, guards against secondary caries, and seals margins against microleakage

Detailed description: To evaluate the cement type (bioactive cement and adhesive resin cement ) on Patient satisfaction ,marginal integrity ,shade matching and gingival health of cemented zirconia reinforced lithium silicate restoration .

PICOTS:

P: patients with missing anterior teeth that needs fixed restoration . I: Bioactive cement. C: adhesive resin cement. O: patient satisfaction ,margin integrity ,shade matching and gingival health T: 1 year

Eligibility criteria: Inclusion Criteria:" Permanent anterior teeth. " Vital teeth with Absence of clinical diagnosis of pulp exposure, periapical pathosis, fistula, swelling of periodontal tissues, abnormal tooth mobility, and history of spontaneous pain or sensitivity to pressure.

" Healthy appearance of adjacent gingiva.

-

Exclusion Criteria:

* Periapical pathosis, Signs of pulpal pathology, Severe periodontal affection these cases are not indicated for full coverage restoration.

Primary outcomes:
measure: margin integrity
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: faculty of oral and dental medicine Cairo university
name: Gihan GN elnagar, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT02021097: Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Official title: A Multicenter, Randomized, Open-labe, Controlled Study to Evaluate the Efficacy and Safety of the Combined Levonorgestrel(LNG) 100mcg and Ethinyl Estradiol(EE) 20mcg for Oral Contraception
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Oral Contraceptive
Keywords: Levonorgestrel；
Ethinyl Estradiol；
Oral Contraceptive
Lead sponsor: Regenex Pharmaceutical, China
Sponsor class: OTHER
First posted: 2013-12-27
Enrollment: 1008
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.


Eligibility criteria: Inclusion Criteria:

* Healthy women,aged 20-35 years who wish to use a contraceptive.
* Women without reproductive system infection complications.
* Willingness to not use other forms of hormonal treatment.
* Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
* Signed informed consent prior to entry into the trial.

Exclusion Criteria:

* Any contraindication to the use of oral contraceptives.
* Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Primary outcomes:
measure: The primary efficacy variable is the number of unintended pregnancies as measured by the Pearl Index (PI) during 13 cycles of treatment
timeFrame: From fist dose to 13 treatment cycles (1 cycle=28 days)
Secondary outcomes:
measure: Menstrual Cycle Control
timeFrame: From fist dose to 13 treatment cycles (1 cycle=28 days)
measure: Weight changes
timeFrame: From fist dose to 13 treatment cycles (1 cycle=28 days)
Other outcomes:
Locations:
city: Beijing
country: China
state: Beijing
city: Beijing
country: China
state: Beijing
city: Chongqing
country: China
state: Chongqing
city: Chongqing
country: China
state: Chongqing
city: Guangzhou
country: China
state: Guangdong
city: Shantou
country: China
state: Guangdong
city: Zhongshan
country: China
state: Guangdong
city: Guiyang
country: China
state: Guizhou
city: Guiyang
country: China
state: Guizhou
city: Wuhan
country: China
state: Hubei
city: Changde
country: China
state: Hunan
city: Changsha
country: China
state: Hunan
city: Nanjing
country: China
state: Jiangsu
city: Nanjing
country: China
state: Jiangsu
city: Yangzhou
country: China
state: Jiangsu
city: Shanghai
country: China
state: Shanghai
city: Taiyuan
country: China
state: Shanxi
city: Xi'an
country: China
state: Shanxi
city: Tianjin
country: China
state: Tianjin
city: Wulumuqi
country: China
state: Xinjiang
city: Taizhou
country: China
state: Zhejiang
Study officials:
affiliation: Family Planning Research Institute of TJMC,HUST
name: Chengliang Xiong, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01956097: Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function
Official title: Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Adults With Subjective Memory Complaints
Lead sponsor: Ewha Womans University
Sponsor class: OTHER
First posted: 2013-10-08
Enrollment: 75
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objectives of the current study are to evaluate the efficacy and safety of HX106 in healthy adults with subjective memory complaints for improving neurocognitive functions and to find the changes of brain using magnetic resonance imaging and their associations with the neurocognitive function enhancement.


Eligibility criteria: Inclusion Criteria:

* Age between 20 and 60 years old,
* Global Deterioration Scale score (GDS) of 2
* One or more symptoms of subjective memory impairment
* High school or higher levels of education.

Exclusion Criteria:

* Current pregnancy or breast-feeding
* Evidence of neurologic or medical conditions
* Axis I diagnosis when assessed by the board certified psychiatrist using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorder, 4th edition (DSM-IV)(SCID-IV),
* One or more major depressive episode during last 12 months
* Mini-mental status examination score of 24 or less
* Clinical Dementia Rating score of 0.5 or more suggesting cognitive impairment beyond self-perceived subjective deficits
* Intelligence quotient less than 80
* Any history of head trauma involving loss of consciousness or seizure
* Contraindications to magnetic resonance imaging (MRI)
* Use of psychotropics in last 3 months
* Use of oral contraceptive medication
* Participation in other clinical trials during the study period that might affect the outcome of the present study.

Primary outcomes:
measure: Changes From Baseline in Working Memory Domain Z-score
timeFrame: Baseline, 8th week
measure: Changes From Baseline in White Matter Integrity Assessment
timeFrame: Baseline, 8th weeks
Secondary outcomes:
measure: Number of Participants With Adverse Events
timeFrame: 1st week
measure: Number of Participants With Adverse Events
timeFrame: 4th weeks
measure: Number of Participants With Adverse Events
timeFrame: 8th weeks
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Ewha W. University
Study officials:
affiliation: Ewha W. University
name: In Kyoon Lyoo, MD, PhD, MMS
role: PRINCIPAL_INVESTIGATOR
References: